Nivolumab Injection
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent and/or Metastatic Platinum-refractory SCCHN
Conditions
Recurrent and/or Metastatic Platinum-refractory SCCHN
Trial Timeline
Jul 7, 2017 → May 31, 2022
NCT ID
NCT03226756About Nivolumab Injection
Nivolumab Injection is a phase 2 stage product being developed by Bristol Myers Squibb for Recurrent and/or Metastatic Platinum-refractory SCCHN. The current trial status is completed. This product is registered under clinical trial identifier NCT03226756. Target conditions include Recurrent and/or Metastatic Platinum-refractory SCCHN.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent and/or Metastatic Platinum-refractory SCCHN were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03715946 | Phase 2 | Completed |
| NCT03226756 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent and/or Metastatic Platinum-refractory SCCHN